HIA
ACAD icon

HFM Investment Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

HFM Investment Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$355 Buy
14
+7
+100% +$154 ﹤0.01% 1091
2026
Q1 		$156 Hold
7
– – ﹤0.01% 1050
2025
Q4 		$187 Sell
7
-2
-22% -$48 ﹤0.01% 1040
2025
Q3 		$192 Buy
9
+2
+29% +$47 ﹤0.01% 1005
2025
Q2 		$151 Buy
+7
New +$130 ﹤0.01% 1069

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

HFM Investment Advisors's ACAD Position: Q2 2026 in Review

HFM Investment Advisors increased its Acadia Pharmaceuticals (ACAD) stake by 100% in Q2 2026, buying an estimated $154 and bringing the position to 14 shares worth $355. The position accounts for ﹤0.01% of the portfolio, ranked #1091.

HFM Investment Advisors first reported a position in ACAD in Q2 2025 and has held it in 5 quarters since. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • HFM Investment Advisors held 14 shares of Acadia Pharmaceuticals worth $355 as of Q2 2026.
  • HFM Investment Advisors bought 7 Acadia Pharmaceuticals shares in Q2 2026, an estimated $154.
  • Acadia Pharmaceuticals made up ﹤0.01% of HFM Investment Advisors's portfolio in Q2 2026, its #1091 holding.
  • HFM Investment Advisors first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on HFM Investment Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.